COPENHAGEN, Denmark, January 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the appointment of Russell Thirsk as Executive…
Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval Opportunity for ColoAlert to become the gold…
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and…
REGULATED INFORMATION Recruitment for ALLOB tibial facture Phase IIb study ongoing and on schedule to release topline data in Q1…
Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in EuropeToronto, Ontario--(Newsfile Corp. - January…
Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…
LEWISVILLE, Texas--(BUSINESS WIRE)--CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), a technology provider to the healthcare industry, today announced…
Financing co-led by venBio Partners & Qiming Venture Partners USA with participation from strong syndicate of new and existing investors…
SAN FRANCISCO--(BUSINESS WIRE)--Tempo Automation, (“Tempo” or the “Company”), a leading software-accelerated electronics manufacturer, and ACE Convergence Acquisition Corp. (“ACE”) (Nasdaq:…
ABX196 phase 1/2 study results for the treatment of hepatocellular carcinoma (HCC) were selected for a presentation at the ASCO…